ADVANCED CARDIAC MONITORING
THE UNMET NEED
More than 900,000 open heart surgeries are conducted each year in the US and EU. While this number has decreased in recent years, the complexity of the patients requiring surgery has increased.
Available techniques for monitoring the function of the heart after surgery tend to be either inaccurate, episodic or involve a high risk to the patient.
Real-time heart function data allows for correct medication, early detection of complications and improved patient recovery, reducing cost for healthcare systems
“A disadvantage is that a catheter needs to be placed in the pulmonary vein. In the lung flow area with a balloon which bears the risk for arrhythmia, lung embolisms and infections. Therefore, in my opinion the disadvantages outweigh the benefit in most cases and therefore it has become so rare.”
(German cardiothoracic surgeon)
01 / SMART LEAD
Temporary pace leads are used routinely during cardiac surgery, all over the world. Cardiaccs' smart lead has an integrated sensor for monitoring cardiac function.
02 / EASY TO USE
Cardiaccs' combined sensor and pace lead is placed and removed in the same way as standard temporary pace leads.
03 / VITAL DATA
Cardiaccs' lead has an embedded accelerometer sensor that measures the velocity of each cardiac contraction. This is a vital parameter for monitoring the cardiac function
“It is additional information that could reveal problems or complications faster than other parameters which have to be detected after a problem is suspected, e.g. a TEE is performed. I could imagine that a problem could be signaled at an earlier stage.”
(German cardiothoracic surgeon)
“The benefits are that you might be able to nip a problem in the bud. Like ischemia and maybe rhythm issues.”
(US cardiothoracic surgeon)
Cardiaccs was founded in 2009 by Prof. Erik Fosse as a result of 8 years of research and development by the Intervention Centre at Oslo University Hospital in cooperation with Buskerud and Vestfold University College. Since February 2016, the company has been ISO 13485 certified for design and development of medical devices.
Cardiovascular related diseases are the leading cause of hospitalization and death worldwide, and there is an increase of patients with complex cases where open heart surgeries are required. Cardiaccs wants to cover the urgent unmet need for better cardiac monitoring to reduce morbidity and mortality in this patient group.
Cardiaccs provides technology for measuring myocardial contractility, a vital parameter for monitoring of the cardiac function. With a continuous and accurate monitoring of the cardiac function, intra- and post-operative complications can be avoided, before a patient becomes critical.
Lucile Souzy - Quality Manager
Lucile holds a masters degree in mechanical engineering and has several years of experience from medical device design, quality and regulatory compliance
MSc Jonas Tyssø - COO
Jonas holds a masters degree in engineering cybernetics from NTNU and has several years of engineering and R&D experience, both within tech startup and multinational IT. Jonas is heading the Cardisense project.
MSc Magnus Krogh - CTO
Magnus Krogh holds a masters degree in Biomedical Engineering and is PhD student at Oslo University where he has worked for several years on methods for monitoring the heart motion. Magnus develops software for the Cardisense technology
BOARD OF DIRECTORS
MD, PhD Erik Fosse - Founder and Chairman
Erik has a lifelong experience as a cardiothoracic surgeon and is head of department at the Intervention Centre at Oslo University Hospital. He has 10 patent applications and has participated in establishing multiple medical companies.
Carl Christian Gilhuus-Moe, PhD, Member of the Board
Dr. Gilhuus-Moe has broad experience from various boards within the medical industry and as chairman of the Board of Oslo Medtech and Sonitor AS. He was the founding President and CEO of Dynal Biotech AS (part of Thermo Fisher Inc.). Dr. Gilhuus-Moe was a member of the executive group, Vice President and head of Hafslund-Nycomed ASA's diagnostic division (part of Abbott Labs).
Ulf Ower, Member of the Board
Ulf is an accountant and has 20 years of experience as economical advisor and business developer. He is CEO/CFO of 5 companies and owner of Finanstorget AS, an authorized accounting company.
Cardiaccs has been ISO 13485 certified for design and development of medical devices since 2016. Quality has been at the center of everything we do, right from the beginning